Back to search results

Observational Study of Lymphoma-associated Hemophagocytic Lymphohistiocytosis

This study is looking at patients who have lymphoma and also develop a serious condition called hemophagocytic lymphohistiocytosis (HLH). HLH is when your immune system overreacts and damages your organs. The study aims to understand what factors predict how long patients with lymphoma-associated HLH will live, specifically looking at survival 180 days after their cancer diagnosis. Researchers will be reviewing past patient information to learn more about the clinical features, lab results, treatments, and outcomes for these patients. You might be eligible if you have lymphoma and meet specific diagnostic criteria for HLH, or if certain blood markers (sCD25 and ferritin) are elevated. This is an observational study, meaning no new treatments are being tested.

Study design
This is a retrospective, multi-institutional observational study. It plans to include up to 2000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your survival would be assessed at 180 days from the malignancy diagnosis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05898477

Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

Recruiting
Not specifiedAll AgesObservational
University of Alabama at Birmingham
~2,000 participants
Updated 2026-01-22 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
Measured over The participant's survival would be assessed at 180 days from the malignancy diagnosis

Conditions

Lymphoma
Hemophagocytic Lymphohistiocytoses

Explore related trials

Hemophagocytic LymphohistiocytosisLymphomaFerritinInterleukin-2 Receptor Subunit Alpha

NCT05898477

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Alabama at Birmingham

    Birmingham, Alabamastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gaurav Goyal, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Gaurav Goyal, MD
[email protected]
205-934-1816
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with lymphoma that are fulfilling at least one of the following:

Exclusion

Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas)
Patients with incomplete treatment and response documentation

What this trial measures

  • To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+The participant's survival would be assessed at 180 days from the malignancy diagnosis

    The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.